Myeloma UK created its first translational myeloma research centre at The Institute of Cancer Research in London (ICR) in 2009. In this time, the ICR has arguably become one of the world’s leading research centres for myeloma.
The research is focused on studying the genetics of myeloma and discovering and developing new effective treatments.
Three research projects make up the programme of research at the ICR:
ORIGINS: looking at samples from patients and non-patients, and from myeloma families to understand why myeloma develops in the first place and then progresses.
ORACLE: looking at myeloma cells from patients to understand what is happening as the myeloma progresses and why treatments stop working. This project is key to finding new, more effective drugs and ultimately a cure.
OPTIMAL: to discover and test new drugs and new combinations of drugs in the lab to understand the best way to treat patients, particularly patients with different genetic profiles.
Our translational research programme is the cornerstone of our collaborative research model that feeds into the Myeloma UK Clinical Trial Network.